Related Experiment Videos
Sulphidopeptide leukotrienes in asthma.
T H Lee1, S P O'Hickey, C Jacques
1Department of Allergy and Allied Respiratory Disorders, Guy's Hospital, London, UK.
Advances in Prostaglandin, Thromboxane, and Leukotriene Research
|January 1, 1991
Summary
Leukotrienes, particularly LTE4, play a significant role in bronchial asthma pathogenesis. These mediators contribute to airway inflammation and hyperresponsiveness, especially in aspirin-induced asthma.
Area of Science:
- Pulmonary Medicine
- Immunology
- Pharmacology
Background:
- Bronchial asthma involves airway inflammation and hyperresponsiveness.
- The exact pathophysiology is complex, likely involving multiple mediators.
- Leukotrienes are implicated due to their properties and presence in asthmatic airways.
Purpose of the Study:
- To investigate the role of leukotrienes in the pathogenesis of bronchial asthma.
- To examine the specific contribution of sulphidopeptide leukotrienes (LTC4, LTD4, LTE4) to airway hyperresponsiveness.
Main Methods:
- Analysis of leukotriene properties and generation by inflammatory cells.
- Assessment of leukotriene presence in asthmatic airways.
- Evaluation of airway responsiveness to inhaled leukotrienes in asthmatic and normal subjects.
Main Results:
- Sulphidopeptide leukotrienes are potent bronchoconstrictors.
- Asthmatic airways show selective hyperresponsiveness to LTE4, unlike LTC4 and LTD4.
- LTE4 may play a unique role in airway hyperresponsiveness and aspirin-induced asthma.
Conclusions:
- Leukotrienes, especially LTE4, are likely contributors to bronchial asthma pathogenesis.
- The selective hyperresponsiveness to LTE4 suggests a specific role in asthma mechanisms.
- Further research into leukotriene pathways could reveal new therapeutic targets for asthma.